Dr Reddy’s unveils wearable migraine management device: stock extends gains

Shares of pharma major Dr Reddy’s Laboratories rose half a percent to Rs 5,561, rallying for the third day in a row on November 17, after the company introduced Nerivio, a United States Food and Drug Administration (USFDA) approved wearable therapy device, for drug-free management of migraine in India.

Nerivio is a prescription-based, non-invasive device designed for the acute and preventive treatment of migraines, both with and without aura, in adults and adolescents aged 12 years and older.

Follow our market blog for all the live action

The device is worn on the upper arm and comes with 18 built-in treatment sessions, each lasting 45 minutes. It is recommended to use the device within 60 minutes of the onset of a migraine for acute treatment or every other day for migraine prevention.

The device employs the Remote Electrical Neuromodulation (REN) mechanism to selectively trigger conditioned pain modulation by stimulating nerve endings. This activation initiates a natural pain-relief process in the brainstem, leading to a widespread effect of pain inhibition that impacts the primary source of migraine pain in the head.

“The roll-out of Nerivio marks our entry into digital therapeutics (DTx). It is an area that is seeing increasing adoption by physicians as well as patients due to its potential to reduce pill burden and decrease dependency on non-specific medication in chronic or hard-to-treat diseases,” said MV Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr Reddy’s.

The Nerivio device comes with an app which will help manage the intensity levels of the device.

“It is a USFDA-approved, drug-free, noninvasive, first-of-its-kind product for migraine in India and offers a favourable safety profile”, the company said in a press release on November 16.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before making any investment decisions.